JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil

NCT07563036 | Recruiting

• 1 other identifier: MS-655-2025
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.

Conditions

Androgenetic Alopecia; Androgenic Alopecia

Keywords

Androgenic Alopecia; Janus Kinase 2; JAK2; minoxidil

Outcome Measures

Primary Outcomes (1)

• Baseline Difference in Tissue JAK2 Protein Levels Between Balding and Non-Balding Scalp

  Comparison of tissue Janus Kinase 2 (JAK2) protein levels measured by ELISA in scalp biopsy specimens obtained at baseline from the balding area (vertex) and the non-balding area (occipital scalp) of participants with androgenetic alopecia.

  Baseline

Secondary Outcomes (3)

• Change in Tissue JAK2 Protein Levels in Balding Scalp After 12 Weeks of Topical Minoxidil

  Baseline to Week 12

• Change in Trichoscopic Hair Parameters After 12 Weeks of Treatment

  Baseline to Week 12

• Correlation Between Change in Tissue JAK2 Levels and Clinical Response

  Week 12

Study Arms (1)

Topical Minoxidil 5% With Scalp Biopsy and JAK2 Assessment

EXPERIMENTAL

Participants with androgenetic alopecia will undergo baseline clinical and trichoscopic assessment, baseline 2 mm punch scalp biopsies from balding and non-balding areas for tissue JAK2 protein measurement by ELISA, treatment with topical minoxidil 5% for 12 weeks, and a repeat 2 mm punch biopsy from the balding scalp after treatment for repeat JAK2 assessment.

Drug: Topical Minoxidil 5% Solution; Procedure: Scalp Punch Biopsy; Diagnostic Test: Tissue JAK2 Protein Measurement by ELISA

Interventions

Topical Minoxidil 5% Solution DRUG

Topical minoxidil 5% solution applied to the affected scalp areas for 12 weeks. Men will apply 1 cc twice daily and women will apply 1 cc once daily.

Topical Minoxidil 5% With Scalp Biopsy and JAK2 Assessment

Scalp Punch Biopsy PROCEDURE

Three 2 mm punch biopsies will be obtained during the study: one from the balding scalp area and one from the non-balding scalp area at baseline, and one from the balding scalp area after 12 weeks of treatment.

Topical Minoxidil 5% With Scalp Biopsy and JAK2 Assessment

Tissue JAK2 Protein Measurement by ELISA DIAGNOSTIC_TEST

Tissue samples obtained from scalp punch biopsies will be analyzed for Janus Kinase 2 (JAK2) protein levels using ELISA at baseline and after 12 weeks of treatment.

Topical Minoxidil 5% With Scalp Biopsy and JAK2 Assessment

Eligibility Criteria

• Age: 18 Years - 50 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male adults aged 18 to 50 years with androgenetic alopecia.
• Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.
• Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.
• Willing and able to provide written informed consent.

You may not qualify if:

• Other types of hair loss, including inflammatory or scarring alopecia.
• Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.
• Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.
• History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
• Chemotherapy during the last 5 years.
• Bleeding disorders.

Sponsors & Collaborators

• Kasr El Aini Hospital: lead

Study Sites (1)

Kasr El Aini Hospital

Cairo, Cairo Governorate, 11555, Egypt

RECRUITING

MeSH Terms

Conditions

Alopecia

Interventions

Minoxidil; Solutions

Condition Hierarchy (Ancestors)

Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrimidines; Pharmaceutical Preparations

Central Study Contacts

Heba Ahmed

CONTACT

+201016532351; heba.a.abdelgayed@kasralainy.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Dermatology

Model Details: Single-arm pre-post interventional study in which all participants with androgenetic alopecia receive topical minoxidil 5% for 12 weeks. Baseline assessments include comparison of balding and non-balding scalp tissue JAK2 expression, followed by reassessment of JAK2 expression in balding scalp after treatment.

Study Record Dates

• First Submitted: April 25, 2026
• First Posted: May 1, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): January 1, 2027
• Last Updated: May 1, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)